Delta-Fly Pharma, Inc. Logo

Delta-Fly Pharma, Inc.

Develops innovative, gentle anticancer agents with reduced side effects for cancer patients.

4598 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
徳島市川内町宮島錦野37番地の5
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Delta-Fly Pharma, Inc. is a biopharmaceutical company specializing in the research and development of anticancer agents. The company utilizes its proprietary "Module Drug Development" concept to create innovative and "gentle" cancer treatments designed to have reduced side effects and be available at a reasonable price. Its development pipeline focuses on small molecule and RNA therapeutics for various cancers, including Acute Myeloid Leukemia. Delta-Fly Pharma's mission is to develop medicines that benefit cancer patients and society through its unique drug discovery approach.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Delta-Fly Pharma, Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-27 08:44
Regulatory News Service
臨時報告書
Japanese 24.4 KB
2025-06-27 08:39
Regulatory News Service
内部統制報告書-第15期(2024/04/01-2025/03/31)
Japanese 23.0 KB
2025-06-27 08:34
Regulatory News Service
確認書
Japanese 8.8 KB
2025-06-27 08:30
Annual Report
有価証券報告書-第15期(2024/04/01-2025/03/31)
Japanese 1.1 MB
2025-04-14 08:30
Prospectus
有価証券届出書(組込方式)
Japanese 289.0 KB
2024-11-14 07:39
Regulatory News Service
確認書
Japanese 8.9 KB
2024-11-14 07:36
Interim Report
半期報告書-第15期(2024/04/01-2025/03/31)
Japanese 180.2 KB
2024-10-07 08:00
Regulatory News Service
臨時報告書
Japanese 22.6 KB
2024-09-20 08:00
Prospectus
有価証券届出書(組込方式)
Japanese 326.2 KB
2024-09-11 08:00
Regulatory News Service
臨時報告書
Japanese 22.8 KB
2024-06-28 08:31
Regulatory News Service
臨時報告書
Japanese 23.5 KB
2024-06-28 08:28
Regulatory News Service
確認書
Japanese 8.8 KB
2024-06-28 08:25
Regulatory News Service
内部統制報告書-第14期(2023/04/01-2024/03/31)
Japanese 22.6 KB
2024-06-28 08:21
Annual Report
有価証券報告書-第14期(2023/04/01-2024/03/31)
Japanese 979.5 KB
2024-02-13 07:20
Regulatory News Service
確認書
Japanese 8.9 KB

Automate Your Workflow. Get a real-time feed of all Delta-Fly Pharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Delta-Fly Pharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Mendus Logo
Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.
Sweden IMMU
Develops AI-driven, glasses-free 3D holographic displays for the defense sector.
United States of America N/A
MicroAd,Inc. Logo
Data-driven marketing tech providing DSP and SSP solutions for digital advertising.
Japan 9553
Microwave Chemical Co., Ltd. Logo
Innovating chemical and metal processing with an eco-friendly microwave platform.
Japan 9227
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan 3636
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan 4883
Model Solution Co., Ltd. Logo
One-stop prototyping & low-volume production for IT, electronics, and medical hardware.
South Korea 417970
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden MODTX
Molecure S.A. Logo
Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.
Poland MOC
Mural Oncology PLC Logo
Clinical-stage company developing cytokine immunotherapies for hard-to-treat solid tumors.
N/A

Talk to a Data Expert

Have a question? We'll get back to you promptly.